First Time Loading...

Exelixis Inc
NASDAQ:EXEL

Watchlist Manager
Exelixis Inc Logo
Exelixis Inc
NASDAQ:EXEL
Watchlist
Price: 23.73 USD -0.54% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. [ Read More ]

The intrinsic value of one EXEL stock under the Base Case scenario is 22.82 USD. Compared to the current market price of 23.73 USD, Exelixis Inc is Overvalued by 4%.

Key Points:
EXEL Intrinsic Value
Base Case
22.82 USD
Overvaluation 4%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Exelixis Inc

Backtest EXEL Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling EXEL stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Exelixis Q4 Revenues Rise; Share Buybacks Continue
2023-Q4 Earnings Call

Exelixis Q4 Revenues Rise; Share Buybacks Continue

Exelixis disclosed a total revenue of $480 million in Q4 2023, with cabozantinib franchise accounting for $429 million. Operating expenses dropped to $398 million from Q3's $490 million due to reduced R&D licensing costs. The company reported a GAAP net income of $85.5 million and a non-GAAP net income of $104.2 million. Completion of a $550 million share repurchase program from March 2023 and an ongoing $450 million program collectively aim to return $1 billion to shareholders by 2024 end. Forecasting a 30% gross to net for 2024, they maintain strong cash reserves of $1.7 billion for internal R&D and business development.

Financials

Balance Sheet Decomposition
Exelixis Inc

Current Assets 1.3B
Cash & Short-Term Investments 995.3m
Receivables 237.4m
Other Current Assets 85.2m
Non-Current Assets 1.6B
Long-Term Investments 728.7m
PP&E 128.7m
Intangibles 63.7m
Other Non-Current Assets 703.3m
Current Liabilities 394.3m
Accounts Payable 33.8m
Accrued Liabilities 192.5m
Other Current Liabilities 168m
Non-Current Liabilities 284.2m
Other Non-Current Liabilities 284.2m
Efficiency

Earnings Waterfall
Exelixis Inc

Revenue
1.8B USD
Cost of Revenue
-72.5m USD
Gross Profit
1.8B USD
Operating Expenses
-1.6B USD
Operating Income
170.9m USD
Other Expenses
36.9m USD
Net Income
207.8m USD

Free Cash Flow Analysis
Exelixis Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

EXEL Profitability Score
Profitability Due Diligence

Exelixis Inc's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Exceptional 3-Years Revenue Growth
Positive Revenue Growth Forecast
60/100
Profitability
Score

Exelixis Inc's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

EXEL Solvency Score
Solvency Due Diligence

Exelixis Inc's solvency score is 79/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Low D/E
Short-Term Solvency
79/100
Solvency
Score

Exelixis Inc's solvency score is 79/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

EXEL Price Targets Summary
Exelixis Inc

Wall Street analysts forecast EXEL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EXEL is 27.27 USD with a low forecast of 18.18 USD and a high forecast of 33.6 USD.

Lowest
Price Target
18.18 USD
23% Downside
Average
Price Target
27.27 USD
15% Upside
Highest
Price Target
33.6 USD
42% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

EXEL Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

EXEL Price
Exelixis Inc

1M 1M
+8%
6M 6M
+9%
1Y 1Y
+24%
3Y 3Y
+7%
5Y 5Y
0%
10Y 10Y
+570%
Annual Price Range
23.73
52w Low
18.17
52w High
24.13
Price Metrics
Average Annual Return -7.79%
Standard Deviation of Annual Returns 17.85%
Max Drawdown -45%
Shares Statistics
Market Capitalization 7.2B USD
Shares Outstanding 303 193 984
Percentage of Shares Shorted 3.36%

EXEL Return Decomposition
Main factors of price return

What is price return decomposition?

EXEL News

Other Videos

Company Profile

Exelixis Inc Logo
Exelixis Inc

Country

United States of America

Industry

Biotechnology

Market Cap

7.2B USD

Dividend Yield

0%

Description

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. The company is headquartered in Alameda, California and currently employs 954 full-time employees. The company went IPO on 2000-04-11. The firm is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Contact

CALIFORNIA
Alameda
1851 Harbor Bay Pkwy
+16508377000.0
http://www.exelixis.com/

IPO

2000-04-11

Employees

954

Officers

Co-Founder & Chair of the Board
Dr. Stelios Papadopoulos Ph.D.
CEO, President & Director
Dr. Michael M. Morrissey Ph.D.
Executive VP & CFO
Mr. Christopher J. Senner
Executive VP, General Counsel & Secretary
Mr. Jeffrey J. Hessekiel J.D.
Executive Vice President of Commercial
Mr. Patrick J. Haley M.B.A.
Executive VP of Discovery and Translational Research & Chief Scientific Officer
Dr. Dana T. Aftab Ph.D.
Show More
Executive Vice President of Public Affairs & Investor Relations
Ms. Susan T. Hubbard
Executive Vice President of Human Resources
Ms. Laura Dillard
Executive VP of Scientific Strategy
Dr. Peter Lamb Ph.D.
Senior Vice President of Drug Safety
Dr. Anne Champsaur M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one EXEL stock?

The intrinsic value of one EXEL stock under the Base Case scenario is 22.82 USD.

Is EXEL stock undervalued or overvalued?

Compared to the current market price of 23.73 USD, Exelixis Inc is Overvalued by 4%.